7 research outputs found
Design of the MWIR channels of EChO
International audienceIn this paper, we present the design of the MWIR channels of EChO. Two channels cover the 5-11 micron spectral range. The choice of the boundaries of each channel is a trade-off driven by the science goals (spectral features of key molecules) and several parameters such as the common optics design, the dichroic plates design, the optical materials characteristics, the detector cut-off wavelength. We also will emphasize the role of the detectors choice that drives the thermal and mechanical designs and the cooling strategy
Peptide aptamers define distinct EB1- and EB3-binding motifs and interfere with microtubule dynamics
Microtubule targeting agents: from biophysics to proteomics
This review explores various aspects of the interaction between microtubule targeting agents and tubulin, including binding site, affinity, and drug resistance. Starting with the basics of tubulin polymerization and microtubule targeting agent binding, we then highlight how the three-dimensional structures of drug-tubulin complexes obtained on stabilized tubulin are seeded by precise biological and biophysical data. New avenues opened by thermodynamics analysis, high throughput screening, and proteomics for the molecular pharmacology of these drugs are presented. The amount of data generated by biophysical, proteomic and cellular techniques shed more light onto the microtubule-tubulin equilibrium and tubulin-drug interaction. Combining these approaches provides new insight into the mechanism of action of known microtubule interacting agents and rapid in-depth characterization of next generation molecules targeting the interaction between microtubules and associated modulators of their dynamics. This will facilitate the design of improved and/or alternative chemotherapies targeting the microtubule cytoskeleton
Microtubule-binding agents: a dynamic field of cancer therapeutics.
International audienceMicrotubules are dynamic filamentous cytoskeletal proteins composed of tubulin and are an important therapeutic target in tumour cells. Agents that bind to microtubules have been part of the pharmacopoeia of anticancer therapy for decades and until the advent of targeted therapy, microtubules were the only alternative to DNA as a therapeutic target in cancer. The screening of a range of botanical species and marine organisms has yielded promising new antitubulin agents with novel properties. In the current search for novel microtubule-binding agents, enhanced tumour specificity, reduced neurotoxicity and insensitivity to chemoresistance mechanisms are the three main objectives